• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >The serum interleukin-26 level is a potential biomarker for chronical hepatitis B
【24h】

The serum interleukin-26 level is a potential biomarker for chronical hepatitis B

机译：血清白细胞介素-26水平是慢性乙型肝炎的潜在生物标志物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Proinflammatory interleukin-26 (IL-26) is involved in chronic inflammation; however, the role of IL-26 in chronic hepatitis B (CHB) remains unknown. In this study, serum IL-26 was quantified in a cohort of CHB patients at baseline and during telbivudine (LdT) treatment. Our results showed that the serum IL-26 level was significantly elevated in CHB patients compared with that in healthy controls and was time-dependently decreased during LdT treatment, accompanying hepatitis B e antigen (HBeAg) seroconversion and reduced serum levels of hepatitis B virus (HBV) DNA, aspartate transaminase, and alanine transaminase across baseline and treatment. In addition, the serum level of IL-26 exhibited a similar declining trend to that of T helper 17 (Th17) cell-secreted IL-17 during LdT treatment in CHB patients. The percentage of IL-26-expressing CD4 + cells was significantly higher than that of IL-26-expressing CD4 - cells isolated from the peripheral blood mononuclear cells of CHB patients, suggesting that serum IL-26 might be mainly released from CD4 + T cells. Furthermore, the baseline mRNA levels of IL-26 and orphan nuclear receptor RORγt—an important transcription factor expressed by Th17 cells—were positively correlated and displayed the same declining trend across the baseline and LdT treatment in CHB patients, suggesting that Th17 cells could be a possible cellular source of the increased serum IL-26 in CHB patients. Taken together, our results suggest that serum IL-26, possibly produced by Th17 CD4 + cells, is a novel and potential biomarker for CHB prognosis and treatment.
机译：促炎性白细胞介素-26（IL-26）参与慢性炎症;然而，IL-26在慢性乙型肝炎（CHB）中的作用仍然未知。在本研究中，血清IL-26在基线的CHB患者队列中量化，并且在左侧致杂化（LDT）处理中。我们的研究结果表明，血清IL-26水平在CHB患者中显着升高，与健康对照相比，在LDT治疗期间与乙型肝炎抗原（HBEAG）血清转化和降低乙型肝炎病毒水平减少的乙型肝炎病毒（ HBV）DNA，天冬氨酸转氨酶和跨基线的丙氨酸转氨酶和治疗。此外，在CHB患者的LDT治疗期间，IL-26的血清IL-26的水平与T Helper 17（Th17）细胞分泌的IL-17的趋势相似。表达IL-26的CD4 +细胞的百分比显着高于CHB患者外周血单核细胞中分离的IL-26表达的CD4细胞的百分比，表明血清IL-26可能主要从CD4 + T释放细胞。此外，IL-26和孤儿核受体RORγT-A17细胞表达的重要转录因子的基线mRNA水平 - 在CHB患者中对基线和LDT治疗相同的趋势并呈现相同的下降趋势，这表明TH17细胞可能是在CHB患者中增加血清IL-26的可能的细胞源。我们的结果表明，可能由Th17 CD4 +细胞产生的血清IL-26是一种新颖的和潜在的生物标志物，用于CHB预后和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号